354 related articles for article (PubMed ID: 25856045)
1. Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability.
van Dijk PR; Groenier KH; DeVries JH; Gans RO; Kleefstra N; Bilo HJ; Logtenberg SJ
Diabetes Technol Ther; 2015 Jun; 17(6):379-84. PubMed ID: 25856045
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal versus subcutaneous insulin therapy in the treatment of type 1 diabetes mellitus.
van Dijk PR; Logtenberg SJ; Hendriks SH; Groenier KH; Feenstra J; Pouwer F; Gans RO; Kleefstra N; Bilo HJ
Neth J Med; 2015 Nov; 73(9):399-409. PubMed ID: 26582805
[TBL] [Abstract][Full Text] [Related]
3. Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up.
van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Kleefstra N; Bilo HJ
BMC Endocr Disord; 2014 Apr; 14():30. PubMed ID: 24708696
[TBL] [Abstract][Full Text] [Related]
4. Report of a 7 year case-control study of continuous intraperitoneal insulin infusion and subcutaneous insulin therapy among patients with poorly controlled type 1 diabetes mellitus: favourable effects on hypoglycaemic episodes.
van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Bilo HJ; Kleefstra N
Diabetes Res Clin Pract; 2014 Nov; 106(2):256-63. PubMed ID: 25305134
[TBL] [Abstract][Full Text] [Related]
5. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial.
Logtenberg SJ; Kleefstra N; Houweling ST; Groenier KH; Gans RO; van Ballegooie E; Bilo HJ
Diabetes Care; 2009 Aug; 32(8):1372-7. PubMed ID: 19429874
[TBL] [Abstract][Full Text] [Related]
6. Poincaré plot quantification for assessing glucose variability from continuous glucose monitoring systems and a new risk marker for hypoglycemia: application to type 1 diabetes patients switching to continuous subcutaneous insulin infusion.
Crenier L
Diabetes Technol Ther; 2014 Apr; 16(4):247-54. PubMed ID: 24237387
[TBL] [Abstract][Full Text] [Related]
7. A New Optimized Percutaneous Access System for CIPII.
Garcia-Verdugo R; Erbach M; Schnell O
J Diabetes Sci Technol; 2017 Jul; 11(4):814-821. PubMed ID: 28654300
[TBL] [Abstract][Full Text] [Related]
8. After 6years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level.
van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
Growth Horm IGF Res; 2015 Dec; 25(6):316-9. PubMed ID: 26336814
[TBL] [Abstract][Full Text] [Related]
9. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes.
van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
J Clin Endocrinol Metab; 2016 Jun; 101(6):2493-501. PubMed ID: 27115061
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Subcutaneous Insulin Infusion Versus Multiple Insulin Injections on Glucose Variability in Young Adults with Type 1 Diabetes: The 2-Year Follow-Up of the Observational METRO Study.
Maiorino MI; Bellastella G; Casciano O; Cirillo P; Simeon V; Chiodini P; Petrizzo M; Gicchino M; Romano O; Caruso P; Giugliano D; Esposito K
Diabetes Technol Ther; 2018 Feb; 20(2):117-126. PubMed ID: 29303370
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of programmable implantable insulin delivery systems.
Olsen CL; Liu G; Iravani M; Nguyen S; Khourdadjian K; Turner DS; Waxman K; Selam JL; Charles MA
Int J Artif Organs; 1993 Dec; 16(12):847-54. PubMed ID: 8175202
[TBL] [Abstract][Full Text] [Related]
12. New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion.
Rieger C; Kurz K; Mueller-Hoffmann W; Gehr B; Liebl A
J Diabetes Sci Technol; 2019 Nov; 13(6):1158-1160. PubMed ID: 31195815
[TBL] [Abstract][Full Text] [Related]
13. Continuous Subcutaneous Insulin Infusion in Adult Type 1 Diabetes Mellitus Patients: Results from a Public Health System.
Moreno-Fernandez J; Gomez FJ; Pinés P; González J; López J; López LM; Blanco B; Roa C; Herranz S; Muñoz-Rodríguez JR
Diabetes Technol Ther; 2019 Aug; 21(8):440-447. PubMed ID: 31199682
[No Abstract] [Full Text] [Related]
14. Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus.
Breton MD; Patek SD; Lv D; Schertz E; Robic J; Pinnata J; Kollar L; Barnett C; Wakeman C; Oliveri M; Fabris C; Chernavvsky D; Kovatchev BP; Anderson SM
Diabetes Technol Ther; 2018 Aug; 20(8):531-540. PubMed ID: 29979618
[TBL] [Abstract][Full Text] [Related]
15. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
[TBL] [Abstract][Full Text] [Related]
16. Islet Transplantation Provides Superior Glycemic Control With Less Hypoglycemia Compared With Continuous Subcutaneous Insulin Infusion or Multiple Daily Insulin Injections.
Holmes-Walker DJ; Gunton JE; Hawthorne W; Payk M; Anderson P; Donath S; Loudovaris T; Ward GM; Kay TW; OʼConnell PJ
Transplantation; 2017 Jun; 101(6):1268-1275. PubMed ID: 27490410
[TBL] [Abstract][Full Text] [Related]
17. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.
Oskarsson PR; Lins PE; Backman L; Adamson UC
Diabetes Metab; 2000 Apr; 26(2):118-24. PubMed ID: 10804326
[TBL] [Abstract][Full Text] [Related]
18. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study.
Buse JB; Kudva YC; Battelino T; Davis SN; Shin J; Welsh JB
Diabetes Technol Ther; 2012 Jul; 14(7):644-7. PubMed ID: 22524549
[TBL] [Abstract][Full Text] [Related]
19. Reducing glucose variability with continuous subcutaneous insulin infusion is associated with reversal of axonal dysfunction in type 1 diabetes mellitus.
Kamel J; Loh M; Cook M; MacIsaac RJ; Roberts LJ
Muscle Nerve; 2020 Jan; 61(1):44-51. PubMed ID: 31613996
[TBL] [Abstract][Full Text] [Related]
20. Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients-a randomized controlled trial.
Bragd J; von Döbeln A; Lins PE; Adamson U; Bergström J; Oskarsson P
Diabetes Technol Ther; 2010 Sep; 12(9):689-93. PubMed ID: 20687863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
